Guide

Clinical investigator inspection history

A clinical investigator’s inspection history is the record of FDA’s inspections of that physician and their site: when each inspection took place, how FDA classified it, which regulations FDA cited, and whether anything followed — a warning letter, a disqualification proceeding. It is the part of a clinical investigator’s qualifications that does not appear on a CV, and one that comes up at the site qualification visit only if the sponsor asks for it.

What an inspection history contains

The inspections. Each FDA Bioresearch Monitoring inspection of the clinical investigator, with the date it closed and the site it covered. Why FDA inspects and what the inspector examines: FDA inspections of clinical investigators.

The classification of each. NAI (No Action Indicated), VAI (Voluntary Action Indicated) or OAI (Official Action Indicated), the most serious inspection classification FDA assigns. FDA assigns it after reviewing the inspection, weeks to months after it closes. What each means: OAI, VAI and NAI.

The findings. Each regulation FDA cited at the inspection, with FDA’s short description of the failure — conducting the study, case histories, informed consent, control of the investigational drug. The areas and how often each is cited: clinical investigator deficiencies.

What followed. A warning letter, if the findings led to one, and its close-out if FDA issued one; a NIDPOE or NOOH letter, if FDA opened disqualification proceedings, and how they ended.

The older record. Inspections from before the modern record began survive on FDA’s clinical investigator inspection lists, which go back to 1977: a date and a classification, without the cited findings.

What it does not contain

An inspection history is FDA’s record, and it is not the complete record. It does not include the Form FDA 483 the inspector left with the clinical investigator, or the clinical investigator’s response to it; those stay with the site. It does not say which study an inspection concerned, and the modern record does not say whether an inspection was routine or for cause. It does not include an inspection FDA has closed but not yet classified. And it says nothing at all about the many clinical investigators FDA has never inspected.

No history is not a clean history. FDA inspects a small share of clinical investigators, chosen largely by which studies support a marketing application. A clinical investigator with no inspections has not been tested; one with an NAI inspection has been. They are different answers, and the site-selection file should say which one it is.

Why it is hard to assemble

FDA sends its findings to the clinical investigator, not typically to the sponsor, and a clinical investigator is not required to tell a sponsor about an inspection unless an agreement says so. A large site runs several sponsors’ trials, so the inspection may have concerned someone else’s study. The record itself is spread across separate datasets and documents — inspections, cited findings, enforcement actions, warning letters, disqualification proceedings, the debarment list — that do not share an identifier, and in which the same physician appears under different spellings and at different sites over a career. Several of the older documents are no longer available from FDA at all. Clinical Precedent assembles them into one record per clinical investigator and site, and keeps the documents.

How to read one

Recency. A newer inspection says more about current practice than an old one. Staff, systems and the clinical investigator’s own attention change over a decade.

The findings, not only the classification. Two VAI inspections can describe very different sites. Findings about informed consent and the protection of subjects generally weigh more than recordkeeping ones, and a finding that touches your protocol’s own risks weighs more than one that does not.

Repetition. One inspection is a snapshot. The same finding at two inspections is a pattern, and repeated or deliberate failure is what FDA itself treats as grounds for disqualification.

The trajectory. A VAI followed by an NAI shows a site that corrected what was found. An NAI followed by an OAI shows the opposite.

The response. For any VAI or OAI, ask the site for the 483 and their responses and corrective action plans. A thorough, documented response is meaningful context, and how readily a site shares it is informative too.

Context. Findings are common in clinical research; most inspections that cite any are classified VAI. What matters is whether this record is typical of the field, better or worse. The field’s numbers: inspection statistics.

Where it fits in selecting a site

A sponsor must select clinical investigators qualified by training and experience (clinical investigator selection), and a clinical investigator’s regulatory history is part of that question. The check many selections run is for warning letters, disqualification and debarment. Those are the rare endings; the inspection history is everything before them, and it is where most of the information is. Reading it is the first step of clinical investigator vetting, and it is best done before the site qualification visit, so that the visit can ask about what the record shows.

When a history shows something that causes concern for the sponsor, the options are the usual three: ask the site for their responses and corrective action plans, visit the site before signing, or choose a site without this history. The history is one input. It does not measure therapeutic expertise, enrollment or the site’s capabilities, and it does not make the decision.

Questions this page answers

What is a clinical investigator’s inspection history?

It is the record of FDA’s inspections of that clinical investigator and their site: the date of each inspection, the classification FDA assigned (NAI, VAI or OAI), the regulations FDA cited, and any warning letter or disqualification proceeding that followed. It is not the complete record of a site: it does not include the Form FDA 483 or the site’s response, and an inspection FDA has not yet classified is not on it.

How far back does a clinical investigator’s FDA inspection history go?

The modern record, with the findings FDA cited at each inspection, begins in fiscal year 2009. FDA’s clinical investigator inspection lists carry older inspections back to 1977, with a date and a classification but not the cited findings.

Does no inspection history mean a clinical investigator is compliant?

No. FDA inspects a small share of clinical investigators, so most have no inspection history at all. No history means FDA has not examined the site; it is neither a good sign nor a bad one. A prior inspection classified NAI is a different and stronger answer.

Will a clinical investigator tell the sponsor about a past FDA inspection?

Often, if asked, but they are not required to unless an agreement says so, and FDA sends its findings to the clinical investigator, not typically to the sponsor. Asking the site is reasonable and worth doing; the FDA record is what confirms the answer is complete.

What should a sponsor do about a finding in a clinical investigator’s inspection history?

Read the finding itself, not only the classification, and weigh how recent it is, whether it repeats and whether it touches the protocol’s own risks. Then the options are three: ask the site for their responses and corrective action plans, visit the site before signing, or choose a site without this history.

Check a name now, free. Screen a clinical investigator against FDA’s disqualification proceedings and debarment list. No account needed.

Run a free status check

Want the inspection record behind it? Inspections, findings and warning letters, benchmarked. Subscriptions start at $249 a month; access is immediate.

See a sample report See plans

About this guide. It is educational, and it is not regulatory or legal advice. The authorities are the Code of Federal Regulations, FDA’s guidance and ICH E6; where this guide and those sources differ, the sources govern.